- Home
- PFL vs LCTX Comparison
PFL vs LCTX Comparison
Compare PFL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | LCTX |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.7M | 391.1M |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PFL | LCTX |
|---|---|---|
| Price | $8.02 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 225.0K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $7.60 | $0.40 |
| 52 Week High | $8.70 | $2.09 |
Technical Indicators
Market Signals| Indicator | PFL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 54.06 |
| Support Level | $7.60 | $1.56 |
| Resistance Level | $8.49 | $1.82 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 80.19 | 74.47 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.